Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

A RANDOMIZED, PHASE II/III STUDY OF PEGYLATED LIPOSOMAL DOXORUBICIN AND CTEP-SUPPLIED ATEZOLIZUMAB (IND #134427) VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN, CTEP-SUPPLIED BEVACIZUMAB AND CTEP-SUPPLIED ATEZOLIZUMAB VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN AND…

Principal Investigator: Lele, Shashikant B

A Multi-phase, Dose-Escalation followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects with Myelodysplastic Syndromes (MDS), Chronic…

Principal Investigator: Griffiths, Elizabeth A

Phase 1/1b Trial of Talazoparib and Gemtuzumab ozogamicin in Adult Patients with Relapsed and/or Refractory Acute Myeloid Leukemia

Principal Investigator: Wang, Eunice S

A Phase 1/2 Open-label, Multicenter Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects with Relapsed or Refractory Large B-cell Lymphoma (ZUMA-19)

Principal Investigator: McCarthy, Philip L

A Phase I/IIa Study of TGFß Blockade in TCR-Engineered T-Cell Cancer Immunotherapy in Patients with Advanced Malignancies

Principal Investigator: Odunsi, Adekunle O

ONCR-177-101 A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of ONCR-177, an Oncolytic Herpes Simplex Virus for Intratumoral Injection, Alone and in Combination with PD-1 Blockade in Adult Subjects with Advanced and/or Refractory…

Principal Investigator: Puzanov, Igor

A Phase 1b/2, Open-Label, Study of Tivozanib in Combination with
Durvalumab in Subjects with Untreated Advanced Hepatocellular Carcinoma

Principal Investigator: Iyer, Renuka V

A Phase 1 Study of OT-82 in Patients with Relapsed or Refractory Non-Hodgkin s Lymphoma

Principal Investigator: Hernandez-Ilizaliturri, Francisco J

A Phase I/ II Trial of Pazopanib Alternating with Bevacizumab in Treatment-Naive Metastatic Clear Cell Renal Cell Carcinoma Patients

Principal Investigator: George, Saby

NCI 10057: A Phase II Study of talimogene laherparepvec (T-VEC) Followed by talimogene laherparepvec (T-VEC) + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors

Principal Investigator: Puzanov, Igor

Close Assessment and Testing for Chronic GVHD (The CATCH Study)

Principal Investigator: Chen, George L

(SWOG S1815) A Phase III Randomized Trial of Gemcitabine, Cisplatin, and NAB-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

Principal Investigator: Iyer, Renuka V

(GRASPANC 2018-01) A Randomized, Phase 3 Study of Eryaspase in Combination with Chemotherapy versus Chemotherapy Alone as Second-Line Treatment in Patients with Pancreatic Adenocarcinoma TRYbeCA-1 TRial of erYaspase in pancreatic Cancer.

Principal Investigator: Fountzilas, Christos

A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients with HER-2 Positive Breast Cancer

Principal Investigator: Gandhi, Shipra

A phase I multi-dose study of human placental hematopoietic stem cell derived natural killer cells (CYNK-001) in adults with newly diagnosed primary or secondary acute myeloid leukemia (AML) in morphologic complete remission with minimal residual disease…

Principal Investigator: Wang, Eunice S

A PHASE 1/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY OF NKTR-262 IN COMBINATION WITH BEMPEGALDESLEUKIN (NKTR-214) AND IN COMBINATION WITH BEMPEGALDESLEUKIN PLUS NIVOLUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID…

Principal Investigator: Puzanov, Igor

A051701Randomized phase II/III study of venetoclax (ABT 199) plus chemoimmunotherapy for MYC/BCL2 double-hit and double-expressing lymphomas

Principal Investigator: Sundaram, Suchitra

EA2187, A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma

Principal Investigator: Iyer, Renuka V

(HCRN ESO17-325) A Phase II Study Evaluating Safety and Efficacy of Niraparib in Patients with Previously Treated Homologous Recombination (HR) Defective or Loss of Heterozygosity (LOH) high Metastatic
Esophageal/Gastroesophageal Junction/Proximal…

Principal Investigator: Fountzilas, Christos

A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib

Principal Investigator: Grand'Maison, Anne C

(S1827)MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

Principal Investigator: Aljabab, Saif A

(A081105) Randomized Study of Erlotinib or Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Principal Investigator: Dy, Grace K

Phase I/ II Study of Pulmonary Suffusion to Control Minimal Residual Disease in Resectable Sarcoma Pulmonary Metastases

Principal Investigator: Demmy, Todd L

ADP-0055-001: A PHASE 1 DOSE ESCALATION STUDY TO ASSESS SAFETY AND EFFICACY OF ADP-A2M4CD8 IN HLA-A2+ SUBJECTS WITH MAGE-A4 POSITIVE TUMORS

Principal Investigator: Odunsi, Adekunle O

(S1922) A Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma

Principal Investigator: Fountzilas, Christos